how to use semaglutide for weight loss The Digital Program Your Patients How to Prepare for Your

Description

BMI should not be used as a sole diagnostic tool

Nearly 25% of the population in western countries have NAFLD and up to 6.5% fulfill the criteria of NASH ( NAFLD is considered the hepatic manifestation of metabolic syndrome ( No pharmacological therapies are approved for the treatment of NAFLD and lifestyle changes focusing on caloric restriction and weight loss constitute the general treatment recommendations

Your body adjusts to a new level of gut motility suppression with each dose escalation

Fiber considerations for tirzepatide (Mounjaro, Zepbound) Tirzepatide is a dual GIP/GLP-1 receptor agonist with a slightly different side effect profile than pure GLP-1 agonists